Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7591 to 7605 of 8901 results

  1. Arimoclomol for treating Niemann-Pick disease Type C [ID1312]

    In development Reference number: GID-HST10037 Expected publication date: TBC

  2. Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma [ID5117]

    In development Reference number: GID-TA11008 Expected publication date: TBC

  3. Ceralasertib with durvalumab for treating advanced non-small-cell lung cancer after antiPD-L1 treatment and platinum-based chemotherapy [ID6612]

    In development Reference number: GID-TA11800 Expected publication date: TBC

  4. Cediranib for treating relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer [ID790]

    Discontinued Reference number: GID-TA10018

  5. Mastocytosis (systemic) - masitinib [ID781]

    Discontinued Reference number: GID-TA10019

  6. Accident and emergency departments

    Discontinued Reference number: GID-SGWAVE0762

  7. Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with neurofibromatosis type 1 [ID6385]

    In development Reference number: GID-TA11457 Expected publication date: TBC

  8. OrganOx metra for liver transplant [ID5116]

    Discontinued Reference number: GID-TA11035

  9. DyeVert Systems for reducing the risk of acute kidney injury in coronary and peripheral angiography (MTG60)

    We have moved Medical technologies guidance 60 to become HealthTech guidance 594. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

  10. KardiaMobile for detecting atrial fibrillation (MTG64)

    We have moved Medical technologies guidance 64 to become HealthTech guidance 606. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

  11. 3C Patch for treating diabetic foot ulcers (MTG66)

    We have moved Medical technologies guidance 66 to become HealthTech guidance 615. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

  12. Synergo for non-muscle-invasive bladder cancer (MTG61)

    We have moved Medical technologies guidance 61 to become HealthTech guidance 601. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

  13. Endo-SPONGE for treating low rectal anastomotic leak (MTG63)

    We have moved Medical technologies guidance 63 to become HealthTech guidance 605. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

  14. Sedaconda ACD-S for sedation with volatile anaesthetics in intensive care (MTG65)

    We have moved Medical technologies guidance 65 to become HealthTech guidance 607. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

  15. Prontosan for treating acute and chronic wounds (MTG67)

    We have moved Medical technologies guidance 67 to become HealthTech guidance 616. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.